ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 517,68
1,22%
Dow Jones
40 589,34
1,64%
DAX
18 417,55
0,62%
Brent Oil
79,745
0,00%
Bitcoin
68 190,13
0,41%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Albireo Pharma Inc (ALBO)

  7. Albireo Pharma Inc (ALBO) Actualités

ALBO

Albireo Pharma (ALBO)

Albireo Pharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALBO
DateHeureSourceTitreSymboleSociété
14/02/202414h33Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALBOAlbireo Pharma Inc
09/03/202312h14Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ALBOAlbireo Pharma Inc
03/03/202312h06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202322h53Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202322h49Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202322h32Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202322h29Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202317h29Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202317h24Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:ALBOAlbireo Pharma Inc
27/02/202322h06Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ALBOAlbireo Pharma Inc
14/02/202322h01Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ALBOAlbireo Pharma Inc
14/02/202314h30GlobeNewswire Inc.FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille SyndromeNASDAQ:ALBOAlbireo Pharma Inc
27/01/202323h29Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:ALBOAlbireo Pharma Inc
23/01/202314h13Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:ALBOAlbireo Pharma Inc
19/01/202322h12Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:ALBOAlbireo Pharma Inc
10/01/202312h07Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:ALBOAlbireo Pharma Inc
21/12/202222h06Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ALBOAlbireo Pharma Inc
20/12/202222h30GlobeNewswire Inc.Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ALBOAlbireo Pharma Inc
19/12/202214h30GlobeNewswire Inc.Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMANASDAQ:ALBOAlbireo Pharma Inc
08/12/202218h35TipRanksWedbush Reaffirms Their Buy Rating on Albireo Pharma (ALBO)NASDAQ:ALBOAlbireo Pharma Inc
06/12/202214h30GlobeNewswire Inc.Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of DirectorsNASDAQ:ALBOAlbireo Pharma Inc
09/11/202214h30GlobeNewswire Inc.Albireo to Participate in Jefferies London Healthcare ConferenceNASDAQ:ALBOAlbireo Pharma Inc
09/11/202212h46TipRanksWedbush Remains a Buy on Albireo Pharma (ALBO)NASDAQ:ALBOAlbireo Pharma Inc
09/11/202212h35TipRanksH.C. Wainwright Remains a Buy on Albireo Pharma (ALBO)NASDAQ:ALBOAlbireo Pharma Inc
08/11/202222h33Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALBOAlbireo Pharma Inc
08/11/202222h01GlobeNewswire Inc.Albireo Reports Q3 2022 Financial Results and Business UpdateNASDAQ:ALBOAlbireo Pharma Inc
07/11/202214h30GlobeNewswire Inc.Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC TypesNASDAQ:ALBOAlbireo Pharma Inc
03/11/202213h30GlobeNewswire Inc.Albireo Announces 2022 SPARK Grant WinnersNASDAQ:ALBOAlbireo Pharma Inc
02/11/202213h30GlobeNewswire Inc.Albireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary AtresiaNASDAQ:ALBOAlbireo Pharma Inc
01/11/202213h30GlobeNewswire Inc.Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022NASDAQ:ALBOAlbireo Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:ALBO

Dernières Valeurs Consultées

SUSHI
MNCETH
MainCoin
KUCN
TTUSDT
ThunderCore
BOV
MILS3
MILLS ON
NYSE
RS
Reliance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés